saklad@uthscsa.edu
Dr Saklad was born in Los Angeles, California. He graduated from Pacific Palisades High School and received his baccalaureate degree in Bacteriology from UCLA. His Doctor of Pharmacy degree was earned at USC in 1978. He did a NIMH fellowship in Psychiatric Pharmacy at the University of Nebraska Medical Center at Omaha in 1978-9 and joined the faculty of The University of Texas College of Pharmacy in 1979. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons born in 1998.
He was the first clinical pharmacist hired by the Texas Department of
Mental Health and Mental Retardation when be began as Clinical Coordinator
at San Antonio State Hospital in 1979.
Dr Saklad has provided care in a variety of settings and treatment roles
at San Antonio State Hospital. Wrote and successfully lobbied for the
creation of a clinical research unit at San Antonio State Hospital funded
by the Texas Legislature and governed by the College of Pharmacy, Department
of Psychiatry and San Antonio State Hospital. He developed the first websites
for the University of Texas College of Pharmacy in 1994 and the College
of Psychiatric and Neurologic Pharmacists (CPNP) in 1997. He is the Director
of the Texas Psychiatric Pharmacy Residency Program in San Antonio. In
2003, he was elected to the Board of Directors of the College of Psychiatric
and Neurologic Pharmacists for a two-year term.
He has published many articles and made many presentations around the
country on a variety of pharmacy and mental health related topics. He
was the editor of Psychopharmacology Update a newsletter founded by Frank
Tornatore from 1998-2002. He has edited two editions of a compendium based
upon this newsletter: Psychopharmacology Desktop Reference, published
by Manisses Communications Group in 1999 and 2002. He is currently the
editor of the Journal of the College of Psychiatric and Neurologic Pharmacists
which began publication as a peer-reviewed online journal in 2002. He
is a principal or co-investigator for several studies of the efficacy
and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia,
mood disorders, and other serious mental illness, as well as their pharmacokinetics
and interactions.